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Abstract  
Introduction: The rapid worldwide spread, in addition to the morbidity and mortality associated with the 
novel coronavirus disease 2019 (COVID-19), have raised concern throughout the world. Identifying the 
characteristics of patients who died of COVID-19 is essential to implement preventive measures.  
Objective: We aimed at investigating these characteristics among the Iranian population in Tabriz. 
Methods: In this case series, we analyzed clinical characteristics, laboratory parameters, and imaging findings 
of 111 patients with a reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed COVID-19 
diagnosis who died during hospitalization. The studied patients had been admitted to the hospital between 
February 2020 and May 2020.  
Results: The median age of patients was 73 years (IQR, 62-82 years) and approximately 70% of them were 
male. The median oxygen saturation on admission was 88% (IQR, 80-92%) and dyspnea, cough, and fever were 
the most common presenting symptoms. Among comorbidities, diabetes, hypertension, and cardiovascular 
diseases were more frequently observed among patients who had a fatal outcome. While ground-glass opacity 
was the most commonly reported finding on chest computed tomography, 5% of the patients had no abnormal 
finding on imaging. Chloroquine was the most frequently used medication for treatment. 
Conclusion: Our results showed that the majority of COVID-19 deaths occurred in male elderly with decreased 
levels of oxygen saturation and elevated levels of lactate dehydrogenase and erythrocyte sedimentation rate on 
admission. 
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INTRODUCTION
In December 2019, a novel coronavirus, now 
formally named as the severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), was 
detected in the lower respiratory tract specimens 
of patients with unknown pneumonia in Hubei 
Province, China (1).  
The disease caused by this virus was subsequently 
named coronavirus disease 2019 (COVID-19) and 
was later declared a pandemic by the World 
Health Organization (WHO). The rapid worldwide 
spread, in addition to the morbidity and mortality 
associated with this viral pathogen raised 
increasing concern throughout the world. 
Meanwhile, it soon became evident that specific 
patient populations are at a higher risk of death 
(2-4). 
The clinical spectrum of COVID-19 ranges from 
mild flu-like symptoms to severe pneumonia 
requiring mechanical ventilation and intensive 
care unit (ICU) admission (5-8). Most of the 
patients with COVID-19 develop a mild form of the 
disease and only 2-5% of the patients experience a 
fatal outcome (9-12). Nevertheless, the mortality 
rate can be as high as 61.5% among those who 
develop critical illness (13).  
Studies have shown that increased risk of death is 
associated with factors, such as older age, 
presence of comorbidities, and specific laboratory 
parameters (14-17). Furthermore, certain 
manifestations and imaging patterns have also 
been shown associated with the patients’ survival. 
However, there is still debate regarding the 
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medications resulting in a greater risk of mortality 
or survival. Similar to other diseases, applying 
appropriate preventive measures is the best 
strategy to manage and control the burden of 
COVID-19. 
Identifying the characteristics of patients who 
died of COVID-19 is essential to implement such 
preventive measures. No study has yet been 
conducted on the characteristics of the Iranian 
patients with COVID-19 who died during 
hospitalization. This study aimed at discussing the 
clinical, laboratory, and imaging findings of a 
subset of fatal cases of COVID-19, as well as the 
medications they had received for the treatment.  
Methods 
Study design and setting  
This multicenter case series was conducted in a 
tertiary care referral center in Tabriz, Iran. The 
research protocol was approved by the Medical 
Ethics Committee of Tabriz University of Medical 
Sciences (IR.TBZMED.REC.1399.008). Informed 
consent was obtained from decedents’ next of kin 
for publication of this study. 
Study population 
The available data from patients with COVID-19 
admitted to the Imam Reza Hospital between 
February 2020 and May 2020 with a fatal outcome 
were gathered and analyzed. No exclusion criteria 
were considered for this study. All patients had a 
confirmed diagnosis of COVID-19 infection by 
reverse transcriptase-polymerase chain reaction 
(RT-PCR). 
Data gathering 
Demographics and clinical characteristics of the 
patients were recorded by collecting data from 
patients’ electronic medical records. Also, 
radiologic findings were recorded after a review of 
the chest computed tomography (CT) scans of 
patients by experienced radiologists. Notably, 
those who had ceased smoking for more than 10 
years were considered as non-smokers. 
Laboratory tests included complete blood count 
(CBC), coagulation tests [prothrombin time (PT), 
international normalized ratio (INR), partial 
thromboplastin time (PTT)], serum albumin, 
sodium (Na), potassium (K), magnesium (Mg), 
phosphorus (P), calcium (ionized and total), 
lactate dehydrogenase (LDH), C-reactive protein 
(CRP), cardiac troponin I, erythrocyte 
sedimentation rate (ESR), creatine kinase MB (CK-
MB), creatine phosphokinase (CPK), blood urea, 
creatinine, aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), alkaline 
phosphatase (ALP), bilirubin (total and direct), 
lipase, and amylase. 
In addition, RT-PCR assay was performed on 
nasopharyngeal specimens for SARS-CoV-2 
detection in all patients using the Taqman® 
Premix TAKARA kit (TaKaRa, Dalian, China) 
considering the protocols provided by the 
manufacturer. In this study, initial laboratory tests 
were analyzed. 
Statistical analysis 
Normal distribution of data was assessed using 
the Shapiro-Wilk test. Categorical data were 
presented as frequency (percentage), and 
continuous data were expressed as mean (± SD) 
for normally distributed data, or median 
[interquartile range (IQR)] for non-normally 
distributed data. All statistical analyses were 
performed using SPSS software version 23 (SPSS 
Inc., Chicago IL, USA). 
RESULTS 
Demographic and baseline clinical 
characteristics 
This study included a total of 111 cases with 
laboratory-confirmed COVID-19 with fatal 
outcome. Demographic and baseline clinical 
characteristics of the patients are presented in 
Table 1. Of the studied cases, 78 patients (70.3%) 
were male and the average age was 73 years (IQR, 
62-82). Figure 1 shows age distribution of study 
fatal cases of COVID-19. The most common 
comorbidities were hypertension, diabetes, and 
cardiovascular diseases (45%, 36.9%, and 21.6%, 
respectively).  
The overlap of the most common comorbidities is 
shown in Figure 2. Only 7 patients (6.3%) were 
smokers. The most frequent presenting symptoms 
on admission were dyspnea, cough, and fever 
(72.1%, 58.6%, and 33.3%, respectively). On 
admission, patients had a mean (± SD) body 
temperature of 37.6 °C (± 1.0) and median oxygen 
saturation of 88% (IQR, 80-92). In addition, the 
median duration of hospitalization was 6 days 
(IQR, 4-11).  
 
Figure 1: Age distribution of fatal cases of COVID-19 
ADVANCED JOURNAL OF EMERGENCY MEDICINE. In press. Nouri-Vaskeh et al 
   
 3 Copyright © 2020 Tehran University of Medical Sciences  
This open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 License (CC BY-NC 4.0). 
 
 
Table 1: Demographics and clinical characteristics of study patients (n=111) 
Variable n (%) 
Sex   
Male 78 (70.3) 
Female 33 (29.7) 
Age, yrs (median, IQR) 73 (62-82) 
Comorbidities   
Hypertension 50 (45) 
Diabetes 41 (36.9) 
Cardiovascular disease 24 (21.6) 
Cerebrovascular disease 13 (11.7) 
Renal disease 11 (9.9) 
Liver disease 4 (3.6) 
Respiratory disease 6 (5.4) 
Other 26 (23.4) 
Smoker 7 (6.3) 
Previous corticosteroid use  1 (0.9) 
Symptoms at admission   
Cough 65 (58.6) 
Myalgia 25 (22.5) 
Dyspnea 80 (72.1) 
Sputum production 8 (7.2) 
Headache 5 (4.5) 
Fever 37 (33.3) 
Diarrhea 5 (4.5) 
Sore throat 2 (1.8) 
Chills 24 (21.6) 
Other  64 (57.7) 
Vital Signs  
Body temperature, °C (mean ± SD) 37.6 (± 1.0) 
Respiratory rate, breaths/min (median, IQR) 20 (18-28) 
Pulse rate, bpm (median, IQR) 92 (80-105) 
Blood pressure, mmHg (median, IQR)  
Systolic blood pressure, mmHg (median, IQR) 120 (110-130) 
Diastolic blood pressure, mmHg (median, IQR) 75 (70-80) 
Oxygen saturation, % (median, IQR) 88 (80-92) 
Duration of hospitalization, days (median, IQR) 6 (4-11) 
Data are presented as n (%), unless stated otherwise. 
 
 
 
Figure 2: Venn diagram of common comorbidities in fatal cases of COVID-19 (CVD, Cardiovascular disease; DM, Diabetes mellitus; 
HTN, Hypertension) 
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Laboratory tests and imaging findings 
The laboratory test results are presented in Table 
2. Frequency of abnormal values are also reported 
in this table. As shown, the median leukocyte 
count was 8.0 × 103/µl (IQR, 5.3-11.3 ×103/µl) and 
39.6% of the patients had abnormal leukocyte 
counts. However, less than one-third of the 
patients had abnormal platelet counts. The 
median ESR and LDH levels were found elevated 
(56.7 mm/h and 688 U/lit, respectively) in 
patients, and also more than 90% of the patients 
had abnormal ESR and CRP levels. Although they 
had elevated median levels of INR and PT (1.15 
and 13.6 s, respectively), the median level of PTT 
was within the normal range (29.2 s); abnormal 
PT and INR levels were seen in approximately 
60% of patients and only 19.8% had an abnormal 
PTT. Also, the patients were found with low serum 
albumin levels (mean= 3.4 g/dl; SD= 0.6).  
On chest CT imaging, ground-glass opacity (GGO) 
was the most commonly observed radiologic 
pattern. No abnormal imaging finding was found 
in 3 patients (4.9%) (Table 3), of whom two cases 
were female (65 and 59 years old) and one was 
male (79 years old); however, two cases had 
hypertension, two cases had fatigue, and one 
patient had a loss of consciousness. Moreover, 
lymphopenia in one patient and neutrophilia and 
thrombocytopenia in another patient were the 
prominent laboratory features.  
Table 2: Initial laboratory tests among study patients 
Variable Value Abnormal, n/N (%) Normal Range 
Leukocyte, ×103 /µl 8.0 (5.3-11.3) 44/111 (39.6) 4.0-10.0 
Lymphocyte      
Percentage 11.0 (6.3-20.4) 77/108 (71.3) 20-40 
Absolute count, ×103 /µl 0.94 (0.64-1.3) 66/108 (61.1) 1.1-3.2 
Hemoglobin, g/dl  12.4 (10.8-13.7)   
Male 12.7 (11.1-13.9) 61/77 (79.2) 14-18  
Female 11.6 (10.4-12.9) 18/30 (60) 12-16 
Platelets, ×103 /µl 182.5 (146.8-244.3) 30/107 (28) 150-450 
Albumin, g/dl 3.4 (± 0.6) 32/94 (34) 3.5-5.2 
Aspartate aminotransferase (AST), U/L 43 (29-63)   
Male 47 (33-75) 59/76 (77.6) 0-31  
Female 37 (25-54) 15/32 (46.9) 0-37 
Alanine aminotransferase (ALT), U/L 30 (19-45)   
Male  32 (21-46) 26/76 (34.2) 0-41  
Female 23 (16-37) 9/32 (28.1) 0-31 
Alkaline phosphatase (ALP), U/L 165 (129-234) 14/71 (19.7) 64-306 
Bilirubin, mg/dl     
Direct 0.4 (0.3-0.5) 24/83 (28.9) 0-0.4 
Total 0.8 (0.6-1.1) 18/83 (21.7) 0.1-1.2 
Prothrombin time, s 13.6 (12.0-15.1) 50/87 (57.5) up to 12.9 
International normalized ratio (INR) 1.15 (1.06-1.31) 54/88 (61.4) 0.9-1.1 
Partial thromboplastin time, s 29.2 (25.9-35.2) 17/86 (19.8) 25-45 
Erythrocyte sedimentation rate (ESR), mm/h 56.7 (± 22.6)   
Male 55.9 (± 22.4) 66/68 (97.1) up to 20 
Female 58.4 (± 23.5) 26/28 (92.8) up to 30 
C-reactive protein (CRP), mg/L 55.5 (32.5-93.4) 78/84 (92.9) up to 10 
Lactate dehydrogenase (LDH), U/L 688 (497-853) 48/62 (77.4) up to 480 
Creatine phosphokinase (CPK), U/L 227 (122-426)   
Male 283 (147-514) 27/54 (50) 39-308  
Female 193 (102-275) 12/24 (50) 26-192 
Creatine kinase MB (CK-MB), U/L 6.75 (2.05-32) 38/54 (70.4) 5-25 
Sodium, mEq/L 137 (133-140) 44/102 (43.1) 136-145 
Potassium, mEq/L 4.2 (3.9-4.6) 24/103 (23.3) 3.6-5 
Calcium, mg/dl 8.3 (7.7-8.9) 56/78 (71.8) 8.6-10.3 
Blood urea, mg/dl 51 (39-102)   
Male 49 (37-93) 43/73 (58.9) 19-44  
Female 64 (41-150) 23/29 (79.3) 15-40 
Creatinine, mg/dl 1.35 (1.10-2.40) 49/104 (47.1) 0.7-1.4 
Lipase, U/L 28 (22-65) 7/36 (19.4) up to 60 
Amylase, U/L 57 (41-79) 3/41 (7.3) up to 100 
Magnesium, mEq/L 2.0 (1.8-2.4) 10/75 (13.3) 1.5-2.5 
Phosphorus, mg/dl 3.8 (2.6-4.7) 32/63 (50.8) 2.6-4.5 
Data are presented as median (IQR) or mean (± SD). 
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DISCUSSION 
In this study, we reported the clinical 
characteristics, laboratory parameters, and 
imaging features of 111 patients who died of 
COVID-19 infection during hospitalization. 
According to our results, there was a male 
predominance in deaths (approximately 70% of 
the total population). This finding is consistent 
with other studies, in which male patients were 
reported at an increased risk of mortality after 
infection with SARS-CoV-2 (4, 18). 
The median age of our patients was 73 years. 
Likewise, other studies showed that the average 
age of patients with COVID-19 who died during 
hospitalization varied between 69 and 71 years 
(16, 18-20). It is well-established that patients 
with COVID-19 commonly present with fever, 
cough, dyspnea, and fatigue (5, 7, 21).  
Similarly, our results showed that in patients who 
died, dyspnea, cough, and fever were more 
common on admission. However, recent studies 
have emphasized gastrointestinal symptoms in 
patients with COVID-19 (22, 23). Only 4.5% of our 
patients complained of diarrhea on admission and 
even lower rates were detected for nausea and 
vomiting. Zhou et al. also found that 4% of non-
survivors had diarrhea on admission (16).  
Notably, patients with fatal outcome had an 
average oxygen saturation of 88% on admission. 
Accordingly, those with the severe disease on 
admission, based on clinical practice guidelines 
(24), should be carefully monitored and need 
additional attention during hospitalization. 
Furthermore, hypertension, diabetes, and 
cardiovascular diseases were the most common 
comorbidities in patients who died during 
hospitalization. According to the current 
literature, patients with these comorbidities have 
increased odds of in-hospital death as well as 
complications associated with COVID-19 (13, 25).   
Regarding laboratory test results, more than 75% 
of the patients had lymphocytopenia (absolute 
lymphocyte count <1500 /µl), which is consistent 
with a report from China  (16). In the present 
study, median levels of LDH and ESR were found 
elevated among patients. Several studies have 
shown that LDH is a laboratory marker that is 
associated with death in patients with COVID-19 
(4, 16).  
Patients with COVID-19 also have coagulation 
abnormalities that are thought to be the 
consequence of endothelial dysfunction, systemic 
inflammation, hypoxia, and immobilization (26, 
27). Consistent with previous findings, we found 
that patients had an increased level of PT and INR; 
however, PTT levels were within the normal 
range. One possible explanation for this finding 
could be the increased factor VIII levels during 
COVID-19 infection.  
During the current outbreak, chest CT imaging has 
played a major role in the detection of suspected 
cases and also in the management of confirmed 
cases of COVID-19. The most common patterns on 
CT imaging in this study were GGO followed by 
GGO/consolidation, and consolidation. We also 
found that about 5% of patients had no abnormal 
finding on CT imaging, suggesting that decision-
making should be based on the combination of 
clinical characteristics, laboratory parameters, 
and radiologic findings.  
The present study evaluated the used medications 
by patients before death. The results showed that 
chloroquine was the most frequent medication 
prescribed for the patients. Only two patients 
(1.8%) had received intravenous immunoglobin 
(IVIG) treatment, which is extremely lower than 
the percentage reported by Zhou et al. (67%) (16). 
Corticosteroids had also not routinely used by 
physicians for the treatment of COVID-19 infection 
in our study, which is another contrary finding 
compared with other studies (16, 18-20). 
Limitations 
Missing data in some variables was the limitation 
of this study. 
CONCLUSIONS 
This retrospective study in Iran showed that the 
majority of fatal cases of COVID-19 were male 
elderly with decreased levels of oxygen saturation 
and elevated levels of LDH and ESR on admission. 
Table 3: Chest computed tomography (CT) findings and 
medications used for treatment of patients 
Variable n (%) 
Imaging findings (n=61)  
Ground-glass opacity (GGO) 37 (60.7) 
Consolidation 8 (13.1) 
GGO/consolidation (mixed) 12 (19.7) 
Pleural effusion 4 (6.6) 
No abnormal finding 3 (4.9) 
Medications (n=111)  
Chloroquine 92 (82.9) 
Ritonavir/Lopinavir 45 (40.5) 
Oseltamivir 51 (45.9) 
Ribavirin 18 (16.2) 
Other 
Antibiotics (oral) 
Antibiotics (IV)  
Antibiotics (IV) + Corticosteroids 
Antibiotics (IV) + Favipiravir 
Antibiotics (IV) + IVIG 
Antibiotics (IV) + Levofloxacin 
Corticosteroids 
 
2 (1.8) 
45 (40.5) 
4 (3.6) 
1 (0.9) 
2 (1.8) 
1 (0.9) 
1 (0.9) 
IV, intravenous; IVIG, intravenous immunoglobulin 
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On imaging, the GGO pattern was the most 
frequent finding and most patients had received 
chloroquine for treatment. 
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